Morstyn G, Burgess A W
Melbourne Tumour Biology Branch, Ludwig Institute for Cancer Research, Australia.
Cancer Res. 1988 Oct 15;48(20):5624-37.
Several hemopoietic growth factors have now been purified, cloned, and produced in bacteria. Granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor are already being used in clinical trials. Within 12 months two more hemopoietic growth factors, macrophage colony stimulating factor (also called colony stimulating factor 1) and interleukin 3 (also called multi-colony stimulating factor) will be used for patient treatment. This review discusses the recent advances in our knowledge of the molecular properties and biological specificities of these factors. It is now clear that these molecules are able to modulate selectively the activity of mature blood cells as well as stimulating the production of specific lineages of blood cells. The availability of recombinant hemopoietic growth factors purified from animal or yeast cell conditioned medium or bacteria has facilitated in vivo experiments, as well as the clinical trials. Each of the growth factors has a unique spectrum of biological activities and it appears that the growth factors will enhance the recovery and function of circulating white blood cells after cancer therapy or bone marrow transplantation.
目前，已有多种造血生长因子被纯化、克隆并在细菌中生产出来。粒细胞集落刺激因子和粒细胞 - 巨噬细胞集落刺激因子已在临床试验中得到应用。在未来12个月内，另外两种造血生长因子，即巨噬细胞集落刺激因子（也称为集落刺激因子1）和白细胞介素3（也称为多集落刺激因子）将用于患者治疗。这篇综述讨论了我们在这些因子的分子特性和生物学特异性方面的最新研究进展。现在已经清楚，这些分子不仅能够刺激特定血细胞谱系的产生，还能够选择性地调节成熟血细胞的活性。从动物或酵母细胞条件培养基或细菌中纯化得到的重组造血生长因子，为体内实验以及临床试验提供了便利。每种生长因子都具有独特的生物活性谱，而且这些生长因子似乎将增强癌症治疗或骨髓移植后循环白细胞的恢复和功能。
